The Patent Finder

Lixte Biotechnology, Inc.

22 patents currently held · Updated Nov 16, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

9
Ending by 2030
Feb 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Jan 14 to 30, 2027 · next Jan 14
  • 2 fees due Mar 3 to 17, 2027 · next Mar 3
  • 2 fees due Jul 9 to 14, 2027 · next Jul 9
  • 1 fee due Sep 19, 2027
    The maintenance fee for Formulations of Oxabicycloheptanes and Oxabicycloheptenes (US 11,931,354) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
  • 1 fee due Oct 14, 2027
    The maintenance fee for Oxabicycloheptane Prodrugs (US 10,618,908) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,426,444Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,822,461Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,079,917Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,023,587Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,399,993Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,143,445HDAC inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,058,268Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,998,957Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,227,473Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,668,062Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 22 patents shown.
Pro members see all 22.
Pro members: see all 22 patents
Also on record, not counted in the 22: 1 patent in force now held by others · 6 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 5 abandoned · 9 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited